A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck (Q44336355)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck |
scientific article |
Statements
1 reference
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck (English)
1 reference
A R Abdul Razak
1 reference
D Soulières
1 reference
S A Laurie
1 reference
S J Hotte
1 reference
S Singh
1 reference
E Winquist
1 reference
S Chia
1 reference
C Le Tourneau
1 reference
P-F Nguyen-Tan
1 reference
E X Chen
1 reference
K K Chan
1 reference
T Wang
1 reference
N Giri
1 reference
C Mormont
1 reference
S Quinn
1 reference
L L Siu
1 reference
28 October 2012
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference